This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

DALE G. FRIEND, M.D.; EDWARD A. EDWARDS, M.D.

AMA Arch Intern Med. 1954;93(6):928-937.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

IN THE management of patients with vascular disease one naturally seeks for a vasodilator drug which will offer substantial vasodilatation in the extremities with minimal effects elsewhere. Such a drug would be particularly useful in so-called Raynaud's syndrome, where it might often obviate the need for surgical sympathectomy, especially for the upper extremity, when the operation is frequently unsatisfactory.

The vasodilator effect of Dibenzyline * (N-phenoxyisopropyl-N-benzyl-β-chloroethylamine hydrochloride) has been briefly reported by several observers. The results in a few patients in whom we tried this drug in 1951 gave promise that Dibenzyline more nearly approached the ideal than other vasodilators with which we were acquainted. This opinion was strengthened by a further use of Dibenzyline over a two-year period for 23 patients suffering from severe digital ischemia, and we, therefore, offer this account of our experiences. We feel that the drug was given a somewhat more rigorous test than . . . [Full Text PDF of this Article]

Author Affiliations
BOSTON

From the Departments of Medicine and Surgery, Peter Bent Brigham Hospital and Harvard Medical School.

Footnotes
Supported in part by Smith, Kline & French Laboratories, Philadelphia.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?